Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA)

  • Read more about A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA)

Cognitive Impairment and Fatigue After Mild to Moderate COVID-19

  • Read more about Cognitive Impairment and Fatigue After Mild to Moderate COVID-19

SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients

  • Read more about SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients

Moderators and Mediators (M & M Trial) of Psychosocial Treatments of Chronic Pain

  • Read more about Moderators and Mediators (M & M Trial) of Psychosocial Treatments of Chronic Pain

Evaluation of Autogenous Demineralized Dentin Graft Vs Autogenous Bone Graft in Management of Intrabony Defects

  • Read more about Evaluation of Autogenous Demineralized Dentin Graft Vs Autogenous Bone Graft in Management of Intrabony Defects

Patients´ Mental and Physical Health After Covid-19 Treated in ICU in Sweden

  • Read more about Patients´ Mental and Physical Health After Covid-19 Treated in ICU in Sweden

Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)

  • Read more about Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

  • Read more about Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

Stellate Ganglion Block with Lidocaine for the Treatment of COVID-19-Induced Parosmia

  • Read more about Stellate Ganglion Block with Lidocaine for the Treatment of COVID-19-Induced Parosmia

MIST Versus M-MIST for the Treatment of Intrabony Defects

  • Read more about MIST Versus M-MIST for the Treatment of Intrabony Defects

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 62
  • Page 63
  • Page 64
  • Page 65
  • Current page 66
  • Page 67
  • Page 68
  • Page 69
  • Page 70
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA